Literature DB >> 12653092

Protocol #0207-545: a phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma.

Mauricio Zanetti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12653092

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  4 in total

Review 1.  Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans.

Authors:  Maurizio Zanetti; Xavier Hernandez; Pierre Langlade-Demoyen
Journal:  Springer Semin Immunopathol       Date:  2005-02-15

2.  Synthesis and delivery of short, noncoding RNA by B lymphocytes.

Authors:  Gonzalo Almanza; Veronika Anufreichik; Jeffrey J Rodvold; Kevin T Chiu; Alexandra DeLaney; Johnny C Akers; Clark C Chen; Maurizio Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

Review 3.  Telomerase immunity from bench to bedside: round one.

Authors:  Xochtil Cortez-Gonzalez; Maurizio Zanetti
Journal:  J Transl Med       Date:  2007-02-26       Impact factor: 5.531

4.  High-efficiency Generation of Multiple Short Noncoding RNA in B-cells and B-cell-derived Extracellular Vesicles.

Authors:  Gonzalo Almanza; Maurizio Zanetti
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-15       Impact factor: 10.183
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.